11-氯-二苯并[b,f][1,4]硫氮杂卓 | 13745-86-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫氮卓类
• 中文名称: 11-氯-二苯并[b,f][1,4]硫氮杂卓
• 中文别名: 喹硫平杂质F
• 英文名称: 11-chloro-dibenzo[b,f][1,4]thiazepine
• 英文别名: 6-chlorobenzo[b][1,4]benzothiazepine
• CAS: 13745-86-3
• 化学式: C₁₃H₈ClNS
• 分子量: 245.732
• InChiKey: ZFOZNNFYECYUQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.7
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  11-氯-二苯并[b,f][1,4]硫氮杂卓 在 哌嗪 、 盐酸 作用下， 以 甲苯 、 乙醇 为溶剂， 25.0~80.0 ℃ 、101.33 kPa 条件下， 生成 11-(1-哌嗪基)二苯并[b,f][1,4]硫氮杂卓盐酸盐(1:1)
  参考文献：
  名称：

  [EN] SYNTHESIS OF 11-(4-[2-(2-HYDROXYETHOXY)ETHYL]- PIPERAZINYL)DIBENZO[B,F][1,4]THIAZEPINE AND ITS FUMARATE SALT
  [FR] SYNTHÈSE DE LL-(4-[2-(2-HYDROXYÉTHOXY)ÉTHYL]- PIPÉRAZINYL)DIBENZO[B,F][1,4]THIAZÉPINE ET DE SES SELS DE FUMARATE

  摘要：

  公开号：

  WO2010001407A8
• 作为产物：
  描述：

  2-氨基二苯硫醚 在 sodium carbonate 、 三氯氧磷 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基苯胺 为溶剂， 生成 11-氯-二苯并[b,f][1,4]硫氮杂卓
  参考文献：
  名称：

  Diversified Synthesis of Novel Quinoline and Dibenzo Thiazepine Derivatives Using Known Active Intermediates

  摘要：

  新型药物的开发以控制常规药物治疗中抗药性感染是当今的需求。通过趋同合成法开发了少量与抗溃疡相关的衍生物。成功合成的衍生物包括二苯并噻嗪啶-吡啶（SLN11-SLN15）和苯并咪唑-氢奎宁基衍生物（SLN16-SLN20）。在最终步骤中采用了微波、超声和常规技术进行耦合。有效的技术被识别为超声技术，主要体现在时间和产率上。报告的化合物通过元素分析和谱学研究（如1H、13C NMR和质谱）进行了结构表征。

  DOI：

  10.14233/ajchem.2013.14818

文献信息

• Design, synthesis and anticancer activity of N-(1-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl derivatives
  作者：Mura Reddy Gudisela、N. Srinivasu、Chaitanya Mulakayala、Praveen Bommu、M.V. Basaveswara Rao、Naveen Mulakayala

  DOI：10.1016/j.bmcl.2017.07.029

  日期：2017.9

  Novel N-(1-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl derivatives were designed, synthesized and their chemical structures were confirmed by 1H NMR, 13C NMR and Mass spectra. The anticancer activities of the newly synthesized compounds were evaluated in vitro against three human cancer cell lines including K562, Colo-205 and MDA-MB 231 by MTT assay. The screening

  设计，合成了新型的N-（1-（4-（二苯并[ b，f ] [1,4]噻嗪pin-11-基）哌嗪-1-基）-1-氧代-3-苯基丙烷-2-基衍生物并通过1 H NMR，13 C NMR和质谱证实了它们的化学结构，并通过MTT法体外评估了新合成的化合物对三种人类癌细胞株K562，Colo-205和MDA-MB 231的抗癌活性。筛选结果表明，5种化合物（16b，16d，16i，16p和16q）表现出强烈的细胞毒性活性，IC 50为50。值介于20和40μM之间。进一步的体外研究表明，抑制沉默调节蛋白可能是这些分子起作用的可能机制。
• [EN] SUBSTITUTED PIPERAZINES OF AZEPINES, OXAZEPINES, AND THIAZEPINES<br/>[FR] PIPERAZINES SUBSTITUTEES D'AZEPINES, D'OXAZEPINES, ET DE THIAZEPINES
  申请人：LILLY CO ELI

  公开号：WO2005026177A1

  公开（公告）日：2005-03-24

  Described herein are antipyschotic compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; R1 is hydrogen, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, or (C1-4) alkyl, wherein the (C1-4) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCH2CH2OH, -CN, imidazolidin-2-one, phenyl, or tetrazole wherein tetrazole is unsubstituted or substituted with (C1-4) alkyl; R2 is H, halogen, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, OR6, SR6, NO2, CN, COR6, C(O)OR6, C(OH)R6, CONR7R8, phenyl or (C1-6) alkyl, wherein the (C1-6) alkyl is unsubstituted or substituted with a hydroxy; R3 is hydrogen, (C 1-6)fluoroalkyl , (C3-6) cycloalkyl, (C 2-6) alkenyl, phenyl, monocyclic heteroaromatic, bicyclic heteroaromatic, or (C1-4)alkyl wherein (C1-4) alkyl is unsubstituted or substituted with a phenyl; R4 and R5 are independently selected from hydrogen, halogen, (C1-6) alkyl, (C1-6) fluoroalkyl, OR9, SR9, NO2, CN, or COR9; R6 is hydrogen, (C1-6) fluoroalkyl, or (C1-6) alkyl; R7 and R8 are independently hydrogen, or (C1-6) alkyl; R9 is hydrogen, (C1-6) fluoroalkyl, (C1-6) alkyl; Alk is (C1-4) alkylene unsubstituted or substituted with a hydroxy; Y is oxygen, sulfur, SO2, or a bond; X is CH2, C=O, S, O, or SO2; Z is hydrogen, halogen, (C1-6) alkyl, (C1-6)fluoroalkyl, -OH, (C1-6) alkoxy, (C1-6) fluoroalkoxy, (C1-6) alkylthio, (C1-6) acyl, (C1-4)alkylsulfonyl, -OCF3, -NO2, - CN, carboxamido which may be substituted on the nitrogen by one or two (C1-4) alkyl groups, and -NH2 in which one of the hydrogens may be replaced by a (C1-4) alkyl group and the other hydrogen may be replaced by either a (C1-4) alkyl group, a (C1-6) acyl group, or a (C1-4) alkylsulfonyl group; the phenyl of R1, R2 or R3 is independently unsubstituted or substituted with one to three substituents independently selected from Z; the monocyclic heteroaromatic of R3 is unsubstituted or substituted with one to three substituents independently selected from Z; the bicyclic heteroaromatic of R3 is unsubstituted or substituted with one to three substituents independently selected from Z; and salts, solvates, and crystal forms thereof. Also described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treatment of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I).

  本文描述了式(I)的抗精神病化合物，其中：是一个可选的苯并五元或六元芳香环，其中含有零至三个异原子，独立选择自N、O和S；R1是氢，(C1-6)氟烷基，(C3-6)环烷基，或(C1-4)烷基，其中(C1-4)烷基未取代或取代为羟基、甲氧基、乙氧基、O OH、-CN、咪唑烷-2-酮、苯基或四氮唑，其中四氮唑未取代或取代为(C1-4)烷基；R2是H、卤素、(C1-6)氟烷基、(C3-6)环烷基、OR6、SR6、NO2、CN、COR6、C(O)OR6、C(OH)R6、CONR7R8、苯基或(C1-6)烷基，其中(C1-6)烷基未取代或取代为羟基；R3是氢，(C1-6)氟烷基，(C3-6)环烷基，(C2-6)烯基，苯基，单环杂芳基，双环杂芳基，或(C1-4)烷基，其中(C1-4)烷基未取代或取代为苯基；R4和R5独立选择自氢、卤素、(C1-6)烷基、(C1-6)氟烷基、OR9、SR9、 、CN或COR9；R6是氢、(C1-6)氟烷基或(C1-6)烷基；R7和R8独立选择自氢或(C1-6)烷基；R9是氢、(C1-6)氟烷基或(C1-6)烷基；Alk是未取代或取代为羟基的(C1-4)烷基；Y是氧、硫、SO2或键；X是CH2、C=O、S、O或SO2；Z是氢、卤素、(C1-6)烷基、(C1-6)氟烷基、-OH、(C1-6)烷氧基、(C1-6)氟烷氧基、(C1-6)烷硫基、(C1-6)酰基、(C1-4)烷基磺酰基、-OCF3、- 、-CN、羧酰胺基，该羧酰胺基可在氮上被一个或两个(C1-4)烷基取代，以及-NH2，其中一个氢原子可被(C1-4)烷基取代，另一个氢原子可被(C1-4)烷基、(C1-6)酰基或(C1-4)烷基磺酰基取代；R1、R2或R3的苯基独立地未取代或取代为从Z中独立选择的一个至三个取代基；R3的单环杂芳基未取代或取代为从Z中独立选择的一个至三个取代基；R3的双环杂芳基未取代或取代为从Z中独立选择的一个至三个取代基；以及其盐、溶剂化合物和晶型形式。还描述了将式(I)的化合物用作多巴胺D2受体拮抗剂和治疗精神病和双相情感障碍的药物，以及式(I)的药物配方。
• Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase
  申请人：Forum Pharmaceuticals, Inc.

  公开号：US20170000749A1

  公开（公告）日：2017-01-05

  This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

  这份披露涉及用于抑制组蛋白去乙酰化酶和治疗认知障碍或缺陷的化合物。更具体地，该披露提供了公式（I）的化合物 其中 Q、J、L和Z如规范中所定义。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS DE L'HISTONE DÉSACÉTYLASE
  申请人：ENVIVO PHARMACEUTICALS INC

  公开号：WO2009137499A1

  公开（公告）日：2009-11-12

  Compounds which are histone deacetylase inhibitors and their use in treating various disorders, including Alzheimer's Disease.

  组合物是组蛋白去乙酰化酶抑制剂，用于治疗各种疾病，包括阿尔茨海默病。
• Nickel‐Catalyzed Amination of (Hetero)aryl Halides Facilitated by a Catalytic Pyridinium Additive
  作者：Dongyang Han、Sasa Li、Siqi Xia、Mincong Su、Jian Jin

  DOI：10.1002/chem.202002800

  日期：2020.9.25

  An efficient and operationally simple Ni‐catalyzed amination protocol has been developed. This methodology features a simple NiII salt, an organic base and catalytic amounts of both a pyridinium additive and Zn metal. A diverse number of (hetero)aryl halides were coupled successfully with primary and secondary alkyl amines, and anilines in good to excellent yields. Similarly, benzophenone imine gave

  已经开发了有效且操作简单的镍催化胺化方案。该方法具有简单的Ni II盐，有机碱以及催化量的吡啶鎓添加剂和Zn金属的特征。多种（杂）芳基卤化物与伯，仲烷基胺和苯胺成功偶联，收率良好。同样，二苯甲酮亚胺以优异的收率得到了相应的N芳基化产物。